Document is current
Any future updates will be listed below
-
Authors
Whitehead, Christopher E.
Ziemke, Elizabeth K.
Frankowski-McGregor, Christy L.
Mumby, Rachel A.
Chung, June
Li, Jinju
Osher, Nathaniel
Coker, Oluwadara
Baladandayuthapani, Veerabhadran
Kopetz, Scott http://orcid.org/0000-0001-9647-3416
Sebolt-Leopold, Judith S. http://orcid.org/0000-0002-0351-8505
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA220199, R01 CA241764, R21 CA267412, R44 CA213715, R41 CA261407, P30 CA046592, R44 CA213715, R41 CA261407)
- License Information
-
More Information
Article History
Received: 23 April 2023
Accepted: 9 May 2024
First Online: 11 July 2024
Competing interests
: C.E.W. has ownership interest in and is an employee of MEKanistic Therapeutics, Inc. VB is a consultant for MEKanistic Therapeutics, Inc. and Phenomics, Inc. S.K. has ownership interest in Lutris, Frontier Medicines and Navire, is a consultant for Genentech, Merck, Boehringer Ingelheim, Bayer Health, Lutris, Pfizer, Mirati Therapeutics, Flame Biosciences, Carina Biotech, Frontier Medicines, Replimune, Bristol-Myers Squibb-Medarex, Amgen, Tempus, Harbinger Oncology, Zentalis, AVEO, Tachyon Therapeutics, Agenus, Revolution Medicines, Kestrel Therapeutics, Regeneron and Roche and receives research funding from Sanofi, Guardant Health, Genentech/Roche, EMD Serono, MedImmune, Novartis, Amgen, Lilly, Daiichi Sankyo, Pfizer, Boehringer Ingelheim, BridgeBio, Cardiff, Jazz, Zentalis and Mirati. J.S.L. has ownership interest in and is a consultant for MEKanistic Therapeutics, Inc. The other authors declare no competing interests. MEKanistic Therapeutics, Inc. provided financial support for the chemical synthesis of MTX-531 and the crystallography studies.
